Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +57

Amgen Earnings Call Highlights Growth Engines, Tax Risk

📊 Amgen reported Q1 earnings with a cautiously upbeat tone, citing solid commercial momentum and upgraded guidance despite market headwinds.

💰 Total product sales grew modestly by 4% year-over-year, driven primarily by breadth across sixteen products with double-digit growth rather than reliance on a single blockbuster.

🚀 Six key high-growth franchises now account for roughly 70% of Amgen's product sales, providing a structural buffer against declining legacy assets.

💉 Repatha led revenue with $876 million in Q1 sales (up 34%), bolstered by new clinical data showing reduced cardiovascular events and growing physician confidence.

🦴 Evenity achieved strong 27% year-over-year growth to reach $562 million, effectively offsetting steep declines in older osteoporosis brands with a dominant U.S. market share.

🔬 The rare disease portfolio accelerated growth by 25% to $1.2 billion, highlighted by near-tripling sales of Eplisna and significant gains from TEPEZZA in oncology.

💊 Oncology and biosimilars segments delivered double-digit gains, with innovative oncology rising 25% to $1.8 billion and biosimilars growing 14% to $835 million.

📈 Amgen upgraded its 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS to $21.70–$23.10, supported by robust free cash flow of $1.5 billion in the quarter.

⚙️ Non-GAAP operating margins stood at 45%, reflecting disciplined cost control while management increased R&D spending by 16% and capital expenditures to $700 million for Q1.

🤖 Artificial intelligence initiatives are delivering operational efficiencies, including halving antibody lead-optimization timelines and drastically reducing production line clearance times.

⚠️ Legacy osteoporosis products face significant challenges with combined Prolia and XGEVA sales down 32%, and management warns of accelerated erosion through 2026 due to biosimilar competition.

💸 Cost of sales rose to 19.5% of product sales, driven by higher royalty obligations and an evolving mix that Amgen expects to remain a near-term headwind for margins.

🏛️ Regulatory setbacks include a proposed FDA withdrawal of approval for Tabneos and paused clinical trials for blinatumomab due to inflammatory events under review.

💸 Amgen faces undisclosed tax risks after receiving a draft IRS Notice challenging profit allocations for the years 2016–2018, adding to its list of financial pressures.

🧬 Pipeline development remains active with Meritide advancing through Phase III trials and Olpasiran showing over 95% reductions in Lp(a) levels in recent studies.

Bullish Signals
  • Amgen reported modest overall sales growth of 4%, driven by high-growth franchises and offsetting pressure from legacy products.
  • Six key growth drivers generated roughly 70% of product sales in Q1 and grew 24% year over year, signaling a structural advantage in the portfolio mix.
  • Sixteen products posted double-digit growth, while 17 are now annualizing above $1 billion in sales, providing a wide base of scale to weather competitive pressures.
  • Repatha led growth with first-quarter sales of $876 million, up 34% year over year, supported by new data showing a 31% reduction in major cardiovascular events.
  • Evenity delivered impressive 27% year-over-year sales growth to $562 million, now holding about 65% of the bone-builder market in the U.S.
  • The rare disease portfolio grew 25% to $1.2 billion, with Eplisna sales nearly tripling to $262 million and TEPEZZA US sales rising 29% to $490 million.
  • Innovative oncology growth reached 25% to $1.8 billion, including significant contributions from Imdeltra ($258 million) and Blincyto (up 12% to $415 million).
  • Biosimilars remained a strong growth pillar with sales up 14% to $835 million, including $280 million from PABLUE in the quarter.
  • Management upgraded 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS guidance to $21.70–$23.10, reflecting confidence in future prospects.
  • Non-GAAP operating margin remained robust at 45%, while the company generated $1.5 billion of free cash flow in the quarter.
  • R&D spending climbed 16% year over year with capital expenditures reaching $700 million in Q1 and approximately $2.6 billion planned for the year to expand manufacturing capacity.
  • AI initiatives have significantly boosted operational efficiency, roughly halving antibody lead-optimization timelines and reducing production line clearance time from 30 minutes to roughly 2 minutes per batch.
Risk Factors
  • Loss of exclusivity is severely impacting legacy osteoporosis products, with combined Prolia and XGEVA sales declining 32% to $1.1 billion in the quarter.
  • Amgen warned of accelerated revenue erosion through 2026 as multiple biosimilars enter the market to compete with aging franchises.
  • The FDA proposed withdrawing approval for Tabneos, highlighting regulatory friction around specific portfolio assets.
  • Clinical trial enrollment for blinatumomab subcutaneous and SLE trials has been paused due to inflammatory events currently under FDA review.
  • Amgen discontinued development of AMG 193, demonstrating inherent risk in its pipeline where projects face discontinuation despite investments.
  • Amgen received a draft IRS Notice of Proposed Adjustment for tax years 2016–2018 challenging profit allocations, introducing significant potential tax liability and compliance costs.
  • Non-GAAP cost of sales rose to 19.5% of product sales driven by higher profit-share and royalty obligations, which management does not expect to ease near term.
Full Analysis
Amgen Inc (AMGN) reported first-quarter earnings and provided an upgraded forward outlook, driven by strong performance in its core growth franchises despite headwinds from legacy product decline and regulatory uncertainties. Total product sales grew 4% year over year, totaling approximately $13.7 billion, fueled primarily by six key drivers that accounted for roughly 70% of revenue and collectively increased 24%. Notable performers included Repatha, which saw first-quarter sales rise 34% to $876 million supported by new cardiovascular subgroup data, and Evenity, which grew 27% overall to $562 million as it solidified its position in the bone-building market. The rare disease portfolio surged 25% to $1.2 billion, led by nearly tripling sales of Eplisna and strong gains in TEPEZZA for cystic fibrosis, while innovative oncology revenues increased 25% to $1.8 billion with Imdeltra contributing significantly. Management maintained high confidence in the company's structural advantage, noting that a broad portfolio of 16 products achieved double-digit growth and 17 now generate over $1 billion annually, reducing reliance on any single blockbuster. Financial metrics remained robust with a non-GAAP operating margin of 45% and free cash flow generation of $1.5 billion for the quarter. Consequently, Amgen upgraded its full-year 2026 revenue guidance to a range of $37.1–$38.5 billion and non-GAAP earnings per share guidance to $21.70–$23.10, reflecting disciplined cost control and increased investment in late-stage pipeline assets like Meritide for hypercholesterolemia and olpasiran for lowering Lp(a). R&D spending increased 16% year over year with capital expenditures reaching $700 million in the first quarter alone, while AI initiatives are already delivering significant operational efficiencies by halving antibody optimization timelines and reducing production clearance times. However, management highlighted several risks that temper long-term optimism, including accelerated erosion of legacy osteoporosis products like Prolia and XGEVA, which fell 32% to $1.1 billion as biosimilar competition intensifies. The company also faces rising cost pressures with non-GAAP cost of sales climbing to 19.5% of product sales due to royalty obligations and a shifting mix, which is expected to persist through the near term. Regulatory challenges add further uncertainty, as the FDA proposed withdrawing approval for Tabneos, paused enrollment in subcutaneous blinatumomab and SLE trials due to inflammatory events, and Amgen discontinued development of AMG 193. Additionally, the company disclosed receipt of a draft IRS Notice of Proposed Adjustment regarding profit allocation for the years 2016–2018, introducing potential tax risks that could impact future earnings. Despite these challenges, Amgen’s strategy focuses on scaling newer growth engines to offset legacy declines and leveraging manufacturing capacity expansions planned at roughly $2.6 billion for the year. The company is preparing for a potential Meritide launch while continuing Phase III trials for key assets like olpasiran, which showed more than 95% reduction in Lp(a) levels. Overall, the earnings call underscores a transition toward a more diversified revenue profile anchored by high-growth franchises, supported by strong cash generation and strategic investments in AI and manufacturing, even as the company navigates external pressures from biosimilars and regulatory scrutiny.